IPO
Radiopharmaceuticals specialist Algeta ASA, of Oslo, Norway, successfully closed its initial public offering, raising NOK 250 million. The offering was more than two times oversubscribed and was in the upper half of the price range at NOK 47 per share.
John Berriman, Chairman of the Board of Algeta, said, “We are delighted to have successfully closed this offering, and very pleased to add so many international institutional specialist investors to our shareholder base.”
The funds raised will allow the company to accelerate the clinical development of its lead product Alpharadin and advance its pipeline of preclinical product candidates towards the clinic.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.